HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Tuberculosis preventive therapy in HIV-infected persons: feasibility issues in developing countries.

Abstract
There is now strong evidence from several randomized controlled trials for the efficacy of preventive therapy in the prevention of tuberculosis in tuberculin skin test positive persons infected with the human immunodeficiency virus (HIV). The World Health Organization and the International Union Against Tuberculosis and Lung Disease recommend preventive therapy for tuberculin skin test positive, HIV-infected persons who do not have active tuberculosis. While implementation of preventive therapy is manageable in industrialised countries because it is affordable and the infrastructure is in place to screen, treat and monitor patients on a regular basis, its implementation in developing countries presents several problems. Feasibility issues such as identification of large numbers of HIV-infected persons, exclusion of active tuberculosis, identification of those most likely to benefit, supervision of preventive therapy and monitoring of adverse drug reactions need to be resolved before tuberculosis preventive therapy can be introduced on a larger scale in developing countries. Possible sites for implementation of a tuberculosis preventive therapy service include voluntary counselling and testing centres for HIV and occupational health clinics for military personnel, hospital or company workers. Feasibility studies need to be carried out to address these issues in developing countries.
AuthorsM P Hawken, D W Muhindi
JournalThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease (Int J Tuberc Lung Dis) Vol. 3 Issue 8 Pg. 646-50 (Aug 1999) ISSN: 1027-3719 [Print] FRANCE
PMID10460096 (Publication Type: Journal Article, Review)
Chemical References
  • Antitubercular Agents
  • Isoniazid
Topics
  • Antitubercular Agents (therapeutic use)
  • Cost-Benefit Analysis
  • Developing Countries
  • HIV Infections (microbiology)
  • Humans
  • Isoniazid (therapeutic use)
  • Treatment Outcome
  • Tuberculosis (prevention & control, virology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: